uploads///Graph

Imbruvica Leads in the Chronic Lymphocytic Leukemia Space

By

Feb. 8 2018, Updated 9:00 a.m. ET

Imbruvica revenue guidance

AbbVie (ABBV) expects Imbruvica to contribute ~$3.3 billion in revenue in 2018, including $2.7 billion worth of sales contributions from the US market.

Imbruvica is co-marketed by AbbVie and Johnson & Johnson (JNJ). To know more about Imbruvica, read AbbVie Expects Peak Sales of $7 Billion for Imbruvica.

Article continues below advertisement

Imbruvica’s 2017 performance

In 4Q17, Imbruvica reported sales of $708 million for AbbVie, a YoY (year-over-year) rise of ~39% on both an operational and a reported basis. The drug also reported US market sales of $585 million, a YoY rise of ~35.3%. In 4Q17, international markets contributed ~$123 million to Imbruvica’s sales attributable to AbbVie, a YoY rise of ~58% on both an operational and a reported basis.

For 2017, the company reported Imbruvica revenue of close to $2.6 billion, a YoY rise of 41% on both an operational and a reported basis. The drug earned revenue of close to $2.1 billion in the US market, a YoY rise of ~36%. In 2017, international markets contributed ~$429 million to Imbruvica’s sales attributable to AbbVie, a YoY rise of ~70% on both an operational and a reported basis.

Imbruvica’s robust revenue performance in 2017 was mainly attributable to its market-leading position across all lines of therapy in the chronic lymphocytic leukemia (or CLL) segment. In 2017, Imbruvica also managed to secure approval from the FDA in two more hematologic oncology indications, including chronic graft-versus-host disease and marginal zone lymphoma.

AbbVie is also exploring Imbruvica as a monotherapy or in combination regimens in several other hematologic oncology indications such as multiple myeloma, non-Hodgkin’s lymphoma, acute myeloid leukemia, and CLL. Imbruvica is thus expected to enable AbbVie to compete effectively with other hematologic oncology players such as Novartis (NVS) and Celgene (CELG).

In the next article, we’ll discuss AbbVie’s oncology drug, Venclexta, in greater detail.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.